Visual Abstract

Complications (macrovascular and microvascular) during the first year of LANDMARC, a 3-year prospective observational study (CTRI/2017/05/008452) that included patients with T2D on ≥2 antihyperglycemic medications, were evaluated. Out of 6236 patients (mean baseline values - age: 52.1 years, T2D duration: 8.6 years and A1C: 8.05%) enrolled, 5654 patients completed first year follow-up. Though the mean A1C improved by 0.45% (baseline: 8.05%) at the end of the first year, macrovascular and microvascular complications were noted in an additional 45 and 93 number of participants, respectively. Neuropathy was the most reported complication (baseline: 11.8% and 1-year: 13.1%). Overall, complications were more common in participants with BMI ≥23 kg/m2, A1C ≥7% or having CV risks factors (Table). A total of 21 deaths were reported of which 15 deaths were attributed to CV causes (myocardial infarction [n=7], sudden death [n=6], stroke and coronary artery procedure [n=1, each]). The 1-year results show a higher trend of complications among those who are overweight, or with suboptimal glycemic control or having CV risk factors. Neuropathy was the predominant T2D complication. The 1-year trends on complications from the real-world LANDMARC study, offer insights into disease progression and suggest the need for controlling risk factors and treatment adjustments in patients with T2D.

Disclosure

N. Rais: None. R. Ghosh: Employee; Self; Sanofi. S. Krishnan: Employee; Self; Sanofi. A. Nair: Employee; Self; Sanofi. S. Mohanasundaram: Employee; Self; Sanofi. S. K. Menon: Employee; Self; Sanofi. V. Salvi: Employee; Self; Sanofi. D. Chodankar: Employee; Self; Sanofi. C. Trivedi: None. S. Wangnoo: None. A. H. Zargar: None. A. K. Das: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Roche Pharma, Sanofi. K. Kumar: Advisory Panel; Self; Sanofi-Aventis. S. Joshi: Advisory Panel; Self; Abbott, AstraZeneca, Biocon, Franco Indian, Glenmark, Lupin, Marico, Roche, Twinhealth, Zydus, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk, Sanofi, Serdia Pharmaceuticals (India) Pvt. Ltd. A. Mithal: Advisory Panel; Self; Eris Lifesciences Limited, Consultant; Self; Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals, Inc., USV Private Limited, Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Novo Nordisk, Sanofi. S. Kalra: Speaker’s Bureau; Self; Eli Lilly and Company, Novo Nordisk, Sanofi. A. Unnikrishnan: Advisory Panel; Self; Sanofi-Aventis, Other Relationship; Self; Novo Nordisk A/S, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes. H. Thacker: None. B. Sethi: None. S. Chowdhury: None.

Funding

Sanofi

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.